For decades, the promise of training the immune system to recognize and destroy a patient's own cancer has outpaced delivery. That gap may finally be narrowing — and the implications for how oncology approaches treatment could be profound, particularly for patients with cancers that respond poorly to checkpoint inhibitors or conventional chemotherapy.

This comprehensive review in Signal Transduction and Targeted Therapy maps the current landscape of personalized cancer vaccine platforms, with particular attention to mRNA-based approaches. Moderna's mRNA-4157 (mRNA-4157/V940) and BioNTech's autogene cevumeran have each demonstrated meaningful reductions in recurrence risk and survival improvements across multiple cancer indications in recent trial data — a notable contrast to the long stagnation symbolized by Sipuleucel-T, which remains the sole FDA-approved therapeutic cancer vaccine after more than a decade. The review systematically characterizes DNA, mRNA, peptide, dendritic cell, and whole-cell vaccine platforms, cataloguing their immunological obstacles: tumor heterogeneity, immunosuppressive microenvironments, and insufficient immune memory formation. Critically, it highlights how nanovaccine architectures — lipid-polymer hybrids, biomimetic tumor membranes, and stimulus-responsive materials — are being engineered to co-deliver neoantigens alongside immunostimulatory agonists, improving lymph node targeting and dendritic cell activation. AI-driven neoantigen selection is also incorporated as a pipeline accelerator.

What distinguishes this moment from prior waves of vaccine optimism is the convergence of three maturing technologies: mRNA manufacturing precision, nanoparticle delivery engineering, and machine learning-assisted antigen prioritization. Individually, each has shown incremental progress; together, they address the core failure modes that have historically doomed cancer vaccine trials. The limitations here are significant — this is a review article synthesizing existing trial and preclinical data, not an independent clinical trial, and many highlighted platforms remain in Phase I or II evaluation with small cohorts. Efficacy signals seen in melanoma or pancreatic cancer settings may not generalize. Still, this synthesis is genuinely valuable as a field-orientation document, and the trajectory it describes — toward truly individualized immune reprogramming — represents one of oncology's most consequential frontiers.